<?xml version="1.0" encoding="UTF-8"?><BillSummaries>
    <item congress="117" measure-type="hr" measure-number="4369" measure-id="id117hr4369" originChamber="HOUSE" orig-publish-date="2021-07-06" update-date="2021-12-01">
        <title>National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021</title>
        <summary summary-id="id117hr4369v53" currentChamber="HOUSE" update-date="2021-12-01">
            <action-date>2021-10-19</action-date>
            <action-desc>Passed House</action-desc>
            <summary-text><![CDATA[ <p><strong>National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021 </strong></p> <p>This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on advanced and continuous pharmaceutical manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)</p>]]></summary-text>
        </summary>
        <summary summary-id="id117hr4369v00" currentChamber="HOUSE" update-date="2021-10-19">
            <action-date>2021-07-06</action-date>
            <action-desc>Introduced in House</action-desc>
            <summary-text><![CDATA[ <p><strong>National Centers of Excellence in Continuous Pharmaceutical Manufacturing Act of 2021 </strong></p> <p>This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education as National Centers of Excellence in Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on continuous manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)</p>]]></summary-text>
        </summary>
    </item>
    <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
        <dc:format>text/xml</dc:format>
        <dc:language>EN</dc:language>
        <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
        <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
        <dc:description>This file contains bill summaries for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
    </dublinCore>
</BillSummaries>
